Bristol-Myers Squibb (BMY) Tops Q1 EPS by 16c; reaffirms guidance

Bristol-Myers Squibb (NYSE: BMY) reported Q1 EPS of $1.58, $0.16 better than the analyst estimate of $1.42. Revenue for the quarter came in at $11.49 billion versus the consensus estimate of $10.92 billion.

GUIDANCE:

Bristol-Myers Squibb sees FY2026 EPS of $6.05-$6.35, versus the consensus of $6.26. Bristol-Myers Squibb sees FY2026 revenue of $46-47.5 billion, versus the consensus of $47.12 billion.

For earnings history and earnings-related data on Bristol-Myers Squibb (BMY) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Star Equity Holdings (STRR) Misses Q2 EPS by 8c
• Home Depot (HD) call put ratio 1.5 calls to 1 put with a focus on September 330 puts into quarter results